The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature

Fabbrocini, Gabriella; Battista, Teresa; Ruggiero, Angelo; Scalvenzi, Massimiliano; Villani, Alessia; Megna, Matteo; Potestio, Luca

doi:10.3390/v15071423

Cited by 4 publications

(2 citation statements)

References 256 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the incidence of flare-ups among psoriasis participants was lower than those estimated by the Vaccine Adverse Event Reporting System Database (14.0% vs. 26.8%), the psoriasis flare-up events seem to distribute equally between arms, suggesting that fID may not help reduce flare. The risk of flare associated with mRNA vaccines and the interruption of methotrexate after vaccination may confound the effect of fID in this matter [ 18 , 46 , 47 ]. Another potential downside of the intradermal vaccination for IMDD patients is the prolonged local reaction.…”

Section: Discussionmentioning

confidence: 99%

Immunogenicity of Intradermal Versus Intramuscular BNT162b2 COVID-19 Booster Vaccine in Patients with Immune-Mediated Dermatologic Diseases: A Non-Inferiority Randomized Controlled Trial

Seree-aphinan,

Rattanakaemakorn,

Suchonwanit

et al. 2024

Vaccines

View full text Add to dashboard Cite

The intradermal route has emerged as a dose-sparing alternative during the coronavirus disease 2019 (COVID-19) pandemic. Despite its efficacy in healthy populations, its immunogenicity has not been tested in immune-mediated dermatologic disease (IMDD) patients. This assessor-blinded, randomized-controlled, non-inferiority trial recruited patients with two representative IMDDs (i.e., psoriasis and autoimmune bullous diseases) to vaccinate with fractionated-dose intradermal (fID) or standard intramuscular (sIM) BNT162b2 vaccines as a fourth booster dose under block randomization stratified by age, sex, and their skin diseases. Post-vaccination SARS-CoV-2-specific IgG and interferon-γ responses measured 4 and 12 weeks post-intervention were serological surrogates used for demonstrating treatment effects. Mean differences in log-normalized outcome estimates were calculated with multivariable linear regression adjusting for their baseline values, systemic immunosuppressants used, and prior COVID-19 vaccination history. The non-inferiority margin was set for fID to retain >80% immunogenicity of sIM. With 109 participants included, 53 received fID (all entered an intention-to-treat analysis). The fID demonstrated non-inferiority to sIM in humoral (mean outcome estimates of sIM: 3.3, ΔfID-sIM [mean, 95%CI]: −0.1, −0.3 to 0.0) and cellular (mean outcome estimates of sIM: 3.2, ΔfID-sIM [mean, 95%CI]: 0.1, −0.2 to 0.3) immunogenicity outcomes. Two psoriasis patients from the fID arm (3.8%) developed injection-site Koebner’s phenomenon. Fewer fID recipients experienced post-vaccination fever (fID vs. sIM: 1.9% vs. 12.5%, p = 0.027). The overall incidence of disease flare-ups was low without a statistically significant difference between groups. The intradermal BNT162b2 vaccine is a viable booster option for IMDD patients troubled by post-vaccination fever; its role in mitigating the risk of flare-ups remains unclear.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunogenicity of Intradermal Versus Intramuscular BNT162b2 COVID-19 Booster Vaccine in Patients with Immune-Mediated Dermatologic Diseases: A Non-Inferiority Randomized Controlled Trial

Seree-aphinan,

Rattanakaemakorn,

Suchonwanit

et al. 2024

Vaccines

View full text Add to dashboard Cite

show abstract

“…Moreover, the exacerbations and new onsets were reported following the first, the second, and the third dose of vaccines, highlighting that each dose may be related to their development. Yet, more studies are needed to discover the pathogenetic mechanisms related to cutaneous reactions following COVID-19 vaccination and to establish its clinical implications [ 6 ].…”

Section: Safety Of Different Types Of Vaccines In Immunocompromised P...mentioning

confidence: 99%

Vaccinations in Selected Immune-Related Diseases Treated with Biological Drugs and JAK Inhibitors—Literature Review and Statement of Experts from Polish Dermatological Society

Narbutt,

Żuber,

Lesiak

et al. 2024

Vaccines

View full text Add to dashboard Cite

The growing use of biological drugs in immune-mediated chronic diseases has undoubtedly revolutionized their treatment. Yet, the topic of vaccinations in this group of patients still raises many concerns and implies many therapeutic problems that require discussion and standardization of management. The aim of this literature review is to present current knowledge regarding safety and efficacy of vaccinations in dermatological and rheumatological patients treated with biological drugs and JAK inhibitors. Additionally, this article provides recommendation from experts of the Polish Dermatological Society about proper use of vaccinations during therapy with biologics. Generally, all live attenuated vaccines are contraindicated during immunosuppressive/immunomodulatory therapy. If there is need, they should be administered long enough prior to the therapy or after cessation. Yet, inactivated vaccines mostly can be safely used, but the problem in this case is the effectiveness of the vaccination. Most studies report that the immune response in patients on biologics after administration of different inactivated vaccines is similar to or even better than in the control group. Thus, the importance of vaccination among patients on biologics must be emphasized to reduce omissions and the fear of possible side effects or insufficient post-vaccination response.

show abstract

Viral reactivation following COVID-19 vaccination: a review of the current literature

Martora,

Megna,

Battista

et al. 2024

Clinical and Experimental Dermatology

View full text Add to dashboard Cite

Background Currently, four vaccines for COVID-19 have been licensed by the European Medi-cines Agency: viral vector-based vaccines (AstraZeneca; AZD1222 and Johnson & Johnson; Ad26.COV2. and 2 mRNA-based vaccines (Pfizer/BioNTech; BNT162b2 and Moderna; mRNA-1273). Since their approval, several cutaneous reactions related to vaccination have been reported in the literature. Among these, viral reactivations are one of the most frequent. Objectives The aim of this manuscript was to investigate current literature regarding viral reactivations following COVID-19 vaccination, focusing the attention on Pityriasis Rosea, Herpes Zoster and Herpes Simplex. Methods A comprehensive literature research using various databases, including metanalyses, re-views, letters to the editor, real-life studies, case series, and reports, was performed. Results A total of 47 articles involving about 2000 patients were selected. Of these, 32, 6 and 17 articles reported VZV reactivation (1,758 cases), HSV (238 cases) onset and PR (71 cases), respectively. Conculsion Possible pathogenetic mechanisms underlying viral reactivation are not still understood as well as the possible correlations between vaccination and viral reactivation should be clarified. Certainly, vaccination should not be discouraged.

show abstract

The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature

Cited by 4 publications

References 256 publications

Immunogenicity of Intradermal Versus Intramuscular BNT162b2 COVID-19 Booster Vaccine in Patients with Immune-Mediated Dermatologic Diseases: A Non-Inferiority Randomized Controlled Trial

Immunogenicity of Intradermal Versus Intramuscular BNT162b2 COVID-19 Booster Vaccine in Patients with Immune-Mediated Dermatologic Diseases: A Non-Inferiority Randomized Controlled Trial

Vaccinations in Selected Immune-Related Diseases Treated with Biological Drugs and JAK Inhibitors—Literature Review and Statement of Experts from Polish Dermatological Society

Viral reactivation following COVID-19 vaccination: a review of the current literature

Contact Info

Product

Resources

About